Skip to main content
main-content
Erschienen in: Zeitschrift für Rheumatologie 1/2016

01.02.2016 | Muskuloskelettaler Schmerz | Empfehlungen und Stellungnahme von Fachgesellschaften

DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR-Therapie muskuloskelettaler Schmerzen

verfasst von: Dr. W. W. Bolten, K. Krüger, S. Reiter-Niesert, D. O. Stichtenoth, Kommission Pharmakotherapie der DGRh

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

NSAR lindern Schmerz und Entzündung durch Hemmung der COX-2 und konsekutive Verminderung der Synthese schmerzvermittelnder Prostaglandine. Unerwünschte Wirkungen limitieren die NSAR-Therapie. Die wichtigsten unerwünschten Wirkungen entstehen gastrointestinal durch Reduzierung der Synthese COX-1-abhängiger protektiver Prostaglandine und kardiovaskulär durch COX-2-Inhibition bzw. durch Verschiebung des Verhältnisses der Syntheserate COX-2- und COX-1-abhängiger pro- und antithrombotisch wirkender Prostaglandine. Besonders gefährdet sind Patienten mit einschlägig erhöhtem Risikoprofil. Strenge Überwachung der Indikation, die Wahl eines selektiven COX-2-Inhibitors oder/und die Komedikation mit einem PPI (ggf. auch Misoprostol) bei GI-Risikopatienten sowie der Einsatz kardioneutraler NSAR (Naproxen, niedrig dosiertes Ibuprofen) bzw. die Vermeidung eher kardial schädigender NSAR (z. B. Coxibe, Diclofenac, hochdosiertes Ibuprofen) bei CV-Risikopatienten sind geeignete Präventivmaßnahmen zur Senkung des NSAR-Risikos. Kontraindikationen wie z. B. eine Niereninsuffizienz (GFR < 30 ml/min) (KI für alle NSAR), Ulkusanamnese (KI für tNSAR) oder kardio- bzw. cerebrovaskuläre Vorerkrankungen (KI für Coxibe) sowie Medikamenteninteraktionen müssen beachtet werden. Therapeutische Entscheidungen werden für jeden Patienten individuell getroffen. Die Behandlungsnotwendigkeit sollte regelmäßig überprüft werden. Das Potenzial nichtmedikamentöser Behandlungsmaßnahmen sollte genutzt werden.
Literatur
1.
Zurück zum Zitat Aithal GP, Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563–575 (vi–vii) PubMed Aithal GP, Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563–575 (vi–vii) PubMed
2.
Zurück zum Zitat Akarca US (2005) Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr Pharm Des 11:1779–1793 PubMed Akarca US (2005) Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr Pharm Des 11:1779–1793 PubMed
3.
Zurück zum Zitat Alcorn N, Madhok R (2015) Non-steroidal anti-inflammatory drugs and venous thromboembolism. Rheumatology (Oxford) 54:570–571 Alcorn N, Madhok R (2015) Non-steroidal anti-inflammatory drugs and venous thromboembolism. Rheumatology (Oxford) 54:570–571
4.
Zurück zum Zitat American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331–1346 American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331–1346
5.
Zurück zum Zitat Armstrong CP, Blower AL (1987) Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527–532 PubMedCentralPubMed Armstrong CP, Blower AL (1987) Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527–532 PubMedCentralPubMed
6.
Zurück zum Zitat Aw TJ, Haas SJ, Liew D et al (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490–496 Aw TJ, Haas SJ, Liew D et al (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490–496
7.
Zurück zum Zitat Awa K, Satoh H, Hori S et al (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 37:469–474 PubMed Awa K, Satoh H, Hori S et al (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 37:469–474 PubMed
8.
Zurück zum Zitat Bianchi Porro G, Lazzaroni M, Imbesi V et al (2000) Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 32:201–208 PubMed Bianchi Porro G, Lazzaroni M, Imbesi V et al (2000) Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 32:201–208 PubMed
9.
Zurück zum Zitat Bianchi Porro G, Lazzaroni M, Manzionna G et al (1998) Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 12:355–360 PubMed Bianchi Porro G, Lazzaroni M, Manzionna G et al (1998) Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 12:355–360 PubMed
10.
Zurück zum Zitat Bjordal JM, Ljunggren AE, Klovning A et al (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329:1317 PubMedCentralPubMed Bjordal JM, Ljunggren AE, Klovning A et al (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329:1317 PubMedCentralPubMed
11.
Zurück zum Zitat Bolten W, Salzmann G, Goldmann R et al (1989) Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint. Z Rheumatol 48:317–322 PubMed Bolten W, Salzmann G, Goldmann R et al (1989) Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint. Z Rheumatol 48:317–322 PubMed
12.
Zurück zum Zitat Bolten W, Waldorf-Bolten E, Sarfert D et al (1990) Pharmacokinetic studies following 2 and 4-week Felbinac gel administration to the knee joint. Z Rheumatol 49:374–377 PubMed Bolten W, Waldorf-Bolten E, Sarfert D et al (1990) Pharmacokinetic studies following 2 and 4-week Felbinac gel administration to the knee joint. Z Rheumatol 49:374–377 PubMed
13.
Zurück zum Zitat Bolten WW, Reiter S, Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie (2012) Empfehlungen zur symptomatischen Therapie mit Opioidanalgetika bei rheumatischen Schmerzen. Z Rheumatol 71:816–822 PubMed Bolten WW, Reiter S, Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie (2012) Empfehlungen zur symptomatischen Therapie mit Opioidanalgetika bei rheumatischen Schmerzen. Z Rheumatol 71:816–822 PubMed
14.
Zurück zum Zitat Bombardier C (2002) An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 89:3D–9D PubMed Bombardier C (2002) An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 89:3D–9D PubMed
15.
Zurück zum Zitat Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528 PubMed Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528 PubMed
16.
Zurück zum Zitat Bourne C, Charpiat B, Charhon N et al (1983) Emergent adverse effects of proton pump inhibitors. Presse Med 42:e53–e62 Bourne C, Charpiat B, Charhon N et al (1983) Emergent adverse effects of proton pump inhibitors. Presse Med 42:e53–e62
17.
Zurück zum Zitat Brun J, Jones R (2001) Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 110:12–13 Brun J, Jones R (2001) Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 110:12–13
18.
Zurück zum Zitat Capone ML, Tacconelli S, Di Francesco L et al (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82:85–94 PubMed Capone ML, Tacconelli S, Di Francesco L et al (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82:85–94 PubMed
19.
Zurück zum Zitat Capone ML, Tacconelli S, Sciulli MG et al (2007) Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322:453–460 PubMed Capone ML, Tacconelli S, Sciulli MG et al (2007) Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322:453–460 PubMed
20.
Zurück zum Zitat Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817 PubMed Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817 PubMed
21.
Zurück zum Zitat Chalmers TC, Berrier J, Hewitt P et al (1988) Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 2(Suppl 1):9–26 PubMed Chalmers TC, Berrier J, Hewitt P et al (1988) Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 2(Suppl 1):9–26 PubMed
22.
Zurück zum Zitat Chan CC, Reid CM, Aw TJ et al (2009) Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 27:2332–2341 PubMed Chan CC, Reid CM, Aw TJ et al (2009) Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 27:2332–2341 PubMed
23.
Zurück zum Zitat Chan FK, Hung LC, Suen BY et al (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127(4):1038–1043 PubMed Chan FK, Hung LC, Suen BY et al (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127(4):1038–1043 PubMed
24.
Zurück zum Zitat Chan FK, Hung LC, Suen BY et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110 PubMed Chan FK, Hung LC, Suen BY et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110 PubMed
25.
Zurück zum Zitat Chan FK, Lanas A, Scheiman J et al (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376:173–179 PubMed Chan FK, Lanas A, Scheiman J et al (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376:173–179 PubMed
26.
Zurück zum Zitat Chan FK, Wong VW, Suen BY et al (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369:1621–1626 PubMed Chan FK, Wong VW, Suen BY et al (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369:1621–1626 PubMed
27.
Zurück zum Zitat Chang C-H, Chen H-C, Lin J-W et al (2011) Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 20:763–771 PubMed Chang C-H, Chen H-C, Lin J-W et al (2011) Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 20:763–771 PubMed
28.
Zurück zum Zitat Chen YF, Jobanputra P, Barton P et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12:1–278 (iii) PubMed Chen YF, Jobanputra P, Barton P et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12:1–278 (iii) PubMed
29.
Zurück zum Zitat Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310:563–572 PubMed Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310:563–572 PubMed
30.
Zurück zum Zitat Conaghan PG, Dickson J, Bolten W et al (2013) A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 52:1303–1312 Conaghan PG, Dickson J, Bolten W et al (2013) A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 52:1303–1312
31.
Zurück zum Zitat Coxib and Traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779 Coxib and Traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779
32.
Zurück zum Zitat Derry S, Moore RA, Rabbie R (2012) Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 9:CD007400 PubMedCentralPubMed Derry S, Moore RA, Rabbie R (2012) Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 9:CD007400 PubMedCentralPubMed
34.
Zurück zum Zitat Dougados M, Simon P, Braun J et al (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70:249–251 PubMed Dougados M, Simon P, Braun J et al (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70:249–251 PubMed
35.
Zurück zum Zitat Dowell D, Kunins HV, Farley TA (2013) Opioid analgesics – risky drugs, not risky patients. JAMA 309:2219–2220 PubMed Dowell D, Kunins HV, Farley TA (2013) Opioid analgesics – risky drugs, not risky patients. JAMA 309:2219–2220 PubMed
36.
Zurück zum Zitat Drug Information System: AiDKlinik® Release 1.9.16 Revision 23502 (2015) Dosing GmbH Heidelberg Drug Information System: AiDKlinik® Release 1.9.16 Revision 23502 (2015) Dosing GmbH Heidelberg
37.
Zurück zum Zitat Dueckers G, Guellac N, Arbogast M et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142:176–193 PubMed Dueckers G, Guellac N, Arbogast M et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142:176–193 PubMed
38.
Zurück zum Zitat European Medicines Agency (2005) European Medicines Agency concludes action on COX-2 inhibitors. European Medicines Agency, London European Medicines Agency (2005) European Medicines Agency concludes action on COX-2 inhibitors. European Medicines Agency, London
39.
Zurück zum Zitat Feagins LA, Cryer BL (2010) Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci 55:226–232 PubMed Feagins LA, Cryer BL (2010) Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci 55:226–232 PubMed
40.
Zurück zum Zitat Fischer-Betz R, Spathling-Mestekemper S (2013) Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 72:669–682 PubMed Fischer-Betz R, Spathling-Mestekemper S (2013) Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 72:669–682 PubMed
41.
Zurück zum Zitat Fortun PJ, Hawkey CJ (2007) Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 23:134–141 PubMed Fortun PJ, Hawkey CJ (2007) Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 23:134–141 PubMed
42.
Zurück zum Zitat Fosbol EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190–197 PubMed Fosbol EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190–197 PubMed
43.
Zurück zum Zitat Freson K, Thys C, Wittevrongel C et al (2006) Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem 6:719–726 PubMed Freson K, Thys C, Wittevrongel C et al (2006) Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem 6:719–726 PubMed
44.
Zurück zum Zitat Fries JF, Murtagh KN, Bennett M et al (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50:2433–2440 PubMed Fries JF, Murtagh KN, Bennett M et al (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50:2433–2440 PubMed
45.
Zurück zum Zitat Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787–796 PubMed Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787–796 PubMed
46.
Zurück zum Zitat Galliard-Grigioni KS, Reinhart WH (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 609:96–99 PubMed Galliard-Grigioni KS, Reinhart WH (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 609:96–99 PubMed
47.
Zurück zum Zitat García Rodríguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with Nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628–1636 PubMed García Rodríguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with Nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628–1636 PubMed
48.
Zurück zum Zitat Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913 PubMed Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913 PubMed
49.
Zurück zum Zitat Goldstein JL, Miner PB Jr., Schlesinger PK (2006) Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 23:1189–1196 PubMed Goldstein JL, Miner PB Jr., Schlesinger PK (2006) Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 23:1189–1196 PubMed
50.
Zurück zum Zitat Gooch K, Culleton BF, Manns BJ et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(280):e281–e287 Gooch K, Culleton BF, Manns BJ et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(280):e281–e287
51.
Zurück zum Zitat Goodson NJ, Brookhart AM, Symmons DPM et al (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367–372 PubMedCentralPubMed Goodson NJ, Brookhart AM, Symmons DPM et al (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367–372 PubMedCentralPubMed
52.
Zurück zum Zitat Gore M, Sadosky A, Leslie D et al (2011) Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 33:1914–1931 PubMed Gore M, Sadosky A, Leslie D et al (2011) Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 33:1914–1931 PubMed
53.
Zurück zum Zitat Graham DY, Agrawal NM, Campbell DR et al (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169–175 PubMed Graham DY, Agrawal NM, Campbell DR et al (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169–175 PubMed
54.
Zurück zum Zitat Griffin MR (2013) High-dose non-steroidal anti-inflammatories: painful choices. Lancet 382:746–748 PubMed Griffin MR (2013) High-dose non-steroidal anti-inflammatories: painful choices. Lancet 382:746–748 PubMed
55.
Zurück zum Zitat Grosser T, Fries S, Fitzgerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4–15 PubMedCentralPubMed Grosser T, Fries S, Fitzgerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4–15 PubMedCentralPubMed
56.
Zurück zum Zitat Grosser T, Yu Y, Fitzgerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 61:17–33 PubMed Grosser T, Yu Y, Fitzgerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 61:17–33 PubMed
57.
Zurück zum Zitat Hawkey CJ (2006) NSAIDs, coxibs, and the intestine. J Cardiovasc Pharmacol 47(Suppl 1):72–75 Hawkey CJ (2006) NSAIDs, coxibs, and the intestine. J Cardiovasc Pharmacol 47(Suppl 1):72–75
58.
Zurück zum Zitat Hawkey CJ, Karrasch JA, Szczepanski L et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727–734 PubMed Hawkey CJ, Karrasch JA, Szczepanski L et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727–734 PubMed
59.
Zurück zum Zitat Hawton K, Bergen H, Simkin S et al (2013) Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 346:f403 PubMedCentralPubMed Hawton K, Bergen H, Simkin S et al (2013) Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 346:f403 PubMedCentralPubMed
60.
Zurück zum Zitat Henao J, Hisamuddin I, Nzerue CM et al (2002) Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 39:1313–1317 PubMed Henao J, Hisamuddin I, Nzerue CM et al (2002) Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 39:1313–1317 PubMed
61.
Zurück zum Zitat Hernandez-Diaz S, Rodriguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093–2099 PubMed Hernandez-Diaz S, Rodriguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093–2099 PubMed
62.
Zurück zum Zitat Hinz B, Brune K (2012) Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 71:20–25 PubMed Hinz B, Brune K (2012) Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 71:20–25 PubMed
63.
Zurück zum Zitat Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474 Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474
64.
Zurück zum Zitat Hooper L, Brown TJ, Elliott R et al (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329:948 PubMedCentralPubMed Hooper L, Brown TJ, Elliott R et al (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329:948 PubMedCentralPubMed
65.
Zurück zum Zitat Huerta C, Castellsague J, Varas-Lorenzo C et al (2005) Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45:531–539 PubMed Huerta C, Castellsague J, Varas-Lorenzo C et al (2005) Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45:531–539 PubMed
66.
Zurück zum Zitat Jarupongprapa S, Ussavasodhi P, Katchamart W (2013) Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 48:830–838 PubMed Jarupongprapa S, Ussavasodhi P, Katchamart W (2013) Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 48:830–838 PubMed
67.
Zurück zum Zitat Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155 PubMedCentralPubMed Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155 PubMedCentralPubMed
68.
Zurück zum Zitat Kearney PM, Baigent C, Godwin J et al (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302–1308 PubMedCentralPubMed Kearney PM, Baigent C, Godwin J et al (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302–1308 PubMedCentralPubMed
69.
Zurück zum Zitat Koch M, Dezi A, Ferrario F et al (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156:2321–2332 PubMed Koch M, Dezi A, Ferrario F et al (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156:2321–2332 PubMed
70.
Zurück zum Zitat Krum H, Swergold G, Gammaitoni A et al (2012) Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 30:342–350 PubMed Krum H, Swergold G, Gammaitoni A et al (2012) Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 30:342–350 PubMed
71.
Zurück zum Zitat Kuijpers T, Van Middelkoop M, Rubinstein SM et al (2011) A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. Eur Spine J 20:40–50 PubMedCentralPubMed Kuijpers T, Van Middelkoop M, Rubinstein SM et al (2011) A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. Eur Spine J 20:40–50 PubMedCentralPubMed
72.
Zurück zum Zitat Lai KC, Chu KM, Hui WM et al (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118:1271–1278 PubMed Lai KC, Chu KM, Hui WM et al (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118:1271–1278 PubMed
73.
Zurück zum Zitat Laine L, Curtis SP, Cryer B et al (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369:465–473 PubMed Laine L, Curtis SP, Cryer B et al (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369:465–473 PubMed
74.
Zurück zum Zitat Laine L, Goldkind L, Curtis SP et al (2009) How common is Diclofenac-associated liver injury? analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 104:356–362 PubMed Laine L, Goldkind L, Curtis SP et al (2009) How common is Diclofenac-associated liver injury? analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 104:356–362 PubMed
75.
Zurück zum Zitat Lanas A, Garcia-Tell G, Armada B et al (2011) Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 9:38 PubMedCentralPubMed Lanas A, Garcia-Tell G, Armada B et al (2011) Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 9:38 PubMedCentralPubMed
76.
Zurück zum Zitat Langman MJ, Weil J, Wainwright P et al (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075–1078 PubMed Langman MJ, Weil J, Wainwright P et al (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075–1078 PubMed
77.
Zurück zum Zitat Lanza FL (1998) A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93:2037–2046 PubMed Lanza FL (1998) A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93:2037–2046 PubMed
78.
Zurück zum Zitat Macdonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361:573–574 PubMed Macdonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361:573–574 PubMed
79.
Zurück zum Zitat Mcgettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8:e1001098 PubMedCentralPubMed Mcgettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8:e1001098 PubMedCentralPubMed
80.
Zurück zum Zitat Mcgettigan P, Henry D (2013) Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 10:e1001388 PubMedCentralPubMed Mcgettigan P, Henry D (2013) Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 10:e1001388 PubMedCentralPubMed
81.
Zurück zum Zitat Mcquay DMRA (1998) An evidence-based resource for pain relief. Oxford University Press, Oxford Mcquay DMRA (1998) An evidence-based resource for pain relief. Oxford University Press, Oxford
83.
Zurück zum Zitat Meek IL, Vonkeman HE, Kasemier J et al (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69:365–371 PubMed Meek IL, Vonkeman HE, Kasemier J et al (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69:365–371 PubMed
84.
Zurück zum Zitat MICROMEDEX® SOLUTIONS (2015) The evidence-based Drug Information System. Truven Health Analytics Inc. © 2015 MICROMEDEX® SOLUTIONS (2015) The evidence-based Drug Information System. Truven Health Analytics Inc. © 2015
85.
Zurück zum Zitat Mitchell JA, Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121–1132 PubMedCentralPubMed Mitchell JA, Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121–1132 PubMedCentralPubMed
86.
Zurück zum Zitat Moon KW, Kim J, Kim JH et al (2011) Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology (Oxford) 50:2278–2282 Moon KW, Kim J, Kim JH et al (2011) Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology (Oxford) 50:2278–2282
87.
Zurück zum Zitat Moore RA, Derry S, Makinson GT et al (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7:R644–R665 PubMedCentralPubMed Moore RA, Derry S, Makinson GT et al (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7:R644–R665 PubMedCentralPubMed
88.
Zurück zum Zitat Moore RA, Derry S, Mcquay HJ (2008) Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am 34:415–432 Moore RA, Derry S, Mcquay HJ (2008) Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am 34:415–432
89.
Zurück zum Zitat Moore RA, Moore OA, Derry S et al (2008) Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther 10:R39 PubMedCentralPubMed Moore RA, Moore OA, Derry S et al (2008) Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther 10:R39 PubMedCentralPubMed
90.
Zurück zum Zitat Moore RA, Moore OA, Derry S et al (2010) Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 69:374–379 PubMedCentralPubMed Moore RA, Moore OA, Derry S et al (2010) Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 69:374–379 PubMedCentralPubMed
91.
Zurück zum Zitat Morrison A, Ramey DR, Van Adelsberg J et al (2007) Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 23:2395–2404 PubMed Morrison A, Ramey DR, Van Adelsberg J et al (2007) Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 23:2395–2404 PubMed
92.
Zurück zum Zitat Mutschler E, Geisslinger G, Kroemer HK et al (2012) Mutschler Arzneimittelwirkungen: Pharmakologie – Klinische Pharmakologie – Toxikologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart Mutschler E, Geisslinger G, Kroemer HK et al (2012) Mutschler Arzneimittelwirkungen: Pharmakologie – Klinische Pharmakologie – Toxikologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart
93.
Zurück zum Zitat National Collaborating Centre for Chronic Conditions, National Institute for Health and Clinical Excellence (2008) Osteoarthritis. The care and management of osteoarthritis in adults. In: Excellence NIfHaC (Hrsg) NICE clinical guideline. NICE, London National Collaborating Centre for Chronic Conditions, National Institute for Health and Clinical Excellence (2008) Osteoarthritis. The care and management of osteoarthritis in adults. In: Excellence NIfHaC (Hrsg) NICE clinical guideline. NICE, London
94.
Zurück zum Zitat Niederberger E, Tegeder I, Vetter G et al (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15:1622–1624 PubMed Niederberger E, Tegeder I, Vetter G et al (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15:1622–1624 PubMed
95.
Zurück zum Zitat Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091 PubMed Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091 PubMed
96.
Zurück zum Zitat O’neil CK, Hanlon JT, Marcum ZA (2012) Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 10:331–342 PubMedCentral O’neil CK, Hanlon JT, Marcum ZA (2012) Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 10:331–342 PubMedCentral
97.
Zurück zum Zitat Ofman JJ, Maclean CH, Straus WL et al (2002) A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 29:804–812 PubMed Ofman JJ, Maclean CH, Straus WL et al (2002) A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 29:804–812 PubMed
98.
Zurück zum Zitat Ostensen M, Foerger F (2009) Management of RA medications in pregnant patients. Nat Rev Rheumatol 5:382–390 PubMed Ostensen M, Foerger F (2009) Management of RA medications in pregnant patients. Nat Rev Rheumatol 5:382–390 PubMed
99.
Zurück zum Zitat Poddubnyy D, Rudwaleit M, Haibel H et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71:1616–1622 PubMed Poddubnyy D, Rudwaleit M, Haibel H et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71:1616–1622 PubMed
100.
Zurück zum Zitat Rahme E, Nedjar H (2007) Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46:435–438 Rahme E, Nedjar H (2007) Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46:435–438
101.
Zurück zum Zitat Ray WA, Stein CM, Daugherty JR et al (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071–1073 PubMed Ray WA, Stein CM, Daugherty JR et al (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071–1073 PubMed
102.
Zurück zum Zitat Regula J, Butruk E, Dekkers CP et al (2006) Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101:1747–1755 PubMed Regula J, Butruk E, Dekkers CP et al (2006) Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101:1747–1755 PubMed
103.
Zurück zum Zitat Reilly IA, Fitzgerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180–186 PubMed Reilly IA, Fitzgerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180–186 PubMed
104.
Zurück zum Zitat Richards D (2004) The Oxford Pain Group League table of analgesic efficacy. Evid Based Dent 5:22–23 Richards D (2004) The Oxford Pain Group League table of analgesic efficacy. Evid Based Dent 5:22–23
105.
Zurück zum Zitat Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512 PubMed Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512 PubMed
106.
Zurück zum Zitat Rostom A, Dube C, Wells G et al (2002) Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. CD002296 Rostom A, Dube C, Wells G et al (2002) Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. CD002296
107.
Zurück zum Zitat Rostom A, Muir K, Dube C et al (2007) Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5:818–828 (828 e811–815; quiz 768) PubMed Rostom A, Muir K, Dube C et al (2007) Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5:818–828 (828 e811–815; quiz 768) PubMed
108.
Zurück zum Zitat Roth SH, Tindall EA, Jain AK et al (1993) A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 153:2565–2571 PubMed Roth SH, Tindall EA, Jain AK et al (1993) A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 153:2565–2571 PubMed
109.
Zurück zum Zitat Scheiman JM, Yeomans ND, Talley NJ et al (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101:701–710 PubMed Scheiman JM, Yeomans ND, Talley NJ et al (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101:701–710 PubMed
110.
Zurück zum Zitat Schiff M, Hochberg MC, Oldenhof J et al (2009) Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 25:2471–2477 PubMed Schiff M, Hochberg MC, Oldenhof J et al (2009) Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 25:2471–2477 PubMed
111.
Zurück zum Zitat Schmidt M (2015) Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use. Dan Med J 62:B4987 PubMed Schmidt M (2015) Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use. Dan Med J 62:B4987 PubMed
112.
Zurück zum Zitat Schneider V, Levesque LE, Zhang B et al (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 164:881–889 PubMed Schneider V, Levesque LE, Zhang B et al (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 164:881–889 PubMed
113.
Zurück zum Zitat Schnitzer TJ, Burmester GR, Mysler E et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665–674 PubMed Schnitzer TJ, Burmester GR, Mysler E et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665–674 PubMed
114.
Zurück zum Zitat Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284:1247–1255 Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284:1247–1255
115.
Zurück zum Zitat Silverstein FE, Graham DY, Senior JR et al (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241–249 PubMed Silverstein FE, Graham DY, Senior JR et al (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241–249 PubMed
116.
Zurück zum Zitat Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387–437 PubMed Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387–437 PubMed
117.
Zurück zum Zitat Singh G (2000) Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 7:115–121 PubMed Singh G (2000) Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 7:115–121 PubMed
118.
Zurück zum Zitat Singh G, Rosen Ramey D (1998) NSAID induced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 51(Suppl.):8–16 Singh G, Rosen Ramey D (1998) NSAID induced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 51(Suppl.):8–16
119.
Zurück zum Zitat Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925 PubMedCentralPubMed Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925 PubMedCentralPubMed
120.
Zurück zum Zitat Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 170:1968–1976 PubMed Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 170:1968–1976 PubMed
121.
Zurück zum Zitat Solomon SD, Mcmurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080 PubMed Solomon SD, Mcmurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080 PubMed
122.
Zurück zum Zitat Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104–2113 PubMedCentralPubMed Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104–2113 PubMedCentralPubMed
123.
Zurück zum Zitat Stichtenoth DO (2004) The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev Med Chem 4:617–624 PubMed Stichtenoth DO (2004) The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev Med Chem 4:617–624 PubMed
124.
Zurück zum Zitat Stichtenoth DO, Wagner B, Frolich JC (1997) Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 45:44–49 Stichtenoth DO, Wagner B, Frolich JC (1997) Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 45:44–49
125.
Zurück zum Zitat Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072 PubMed Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072 PubMed
126.
Zurück zum Zitat Tielemans MM, Eikendal T, Jansen JB et al (2010) Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 33:443–453 PubMed Tielemans MM, Eikendal T, Jansen JB et al (2010) Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 33:443–453 PubMed
127.
Zurück zum Zitat Tleyjeh IM, Bin Abdulhak AA, Riaz M et al (2012) Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis. PloS One 7:e50836 PubMedCentralPubMed Tleyjeh IM, Bin Abdulhak AA, Riaz M et al (2012) Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis. PloS One 7:e50836 PubMedCentralPubMed
128.
Zurück zum Zitat Tramer MR, Moore RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169–182 Tramer MR, Moore RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169–182
129.
Zurück zum Zitat Tramer MR, Williams JE, Carroll D et al (1998) Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand 42:71–79 Tramer MR, Williams JE, Carroll D et al (1998) Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand 42:71–79
130.
Zurück zum Zitat Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086 PubMedCentralPubMed Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086 PubMedCentralPubMed
131.
Zurück zum Zitat Ungprasert P, Srivali N, Wijarnpreecha K et al (2015) Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford) 54:736–742 Ungprasert P, Srivali N, Wijarnpreecha K et al (2015) Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford) 54:736–742
132.
Zurück zum Zitat Vandraas KF, Spigset O, Mahic M et al (2010) Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 66:823–829 PubMed Vandraas KF, Spigset O, Mahic M et al (2010) Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 66:823–829 PubMed
133.
Zurück zum Zitat Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235 PubMed Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235 PubMed
134.
Zurück zum Zitat Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 20:1225–1236 PubMed Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 20:1225–1236 PubMed
135.
Zurück zum Zitat Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559–570 PubMedCentralPubMed Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559–570 PubMedCentralPubMed
136.
Zurück zum Zitat Vonkeman HE, Fernandes RW, Van De Laar MA (2007) Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 45:281–288 PubMed Vonkeman HE, Fernandes RW, Van De Laar MA (2007) Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 45:281–288 PubMed
137.
Zurück zum Zitat Vonkeman HE, Van De Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39:294–312 PubMed Vonkeman HE, Van De Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39:294–312 PubMed
138.
Zurück zum Zitat Wang X, Tian HJ, Yang HK et al (2011) Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 23:876–880 PubMed Wang X, Tian HJ, Yang HK et al (2011) Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 23:876–880 PubMed
139.
Zurück zum Zitat Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790–804 PubMed Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790–804 PubMed
140.
Zurück zum Zitat Wilcox CM, Cryer B, Triadafilopoulos G (2005) Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 32:2218–2224 PubMed Wilcox CM, Cryer B, Triadafilopoulos G (2005) Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 32:2218–2224 PubMed
141.
Zurück zum Zitat Wilkinson R (1994) Analgesic and NSAID-induced Kidney Disease. BMJ 308:1309 Wilkinson R (1994) Analgesic and NSAID-induced Kidney Disease. BMJ 308:1309
143.
Zurück zum Zitat Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719–726 PubMed Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719–726 PubMed
144.
Zurück zum Zitat Yu Y, Ricciotti E, Scalia R et al (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4:132ra54 (132ra154) PubMed Yu Y, Ricciotti E, Scalia R et al (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4:132ra54 (132ra154) PubMed
145.
Zurück zum Zitat Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619–1632 PubMed Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619–1632 PubMed
146.
Zurück zum Zitat Zhang W, Doherty M, Arden N et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64:669–681 PubMedCentralPubMed Zhang W, Doherty M, Arden N et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64:669–681 PubMedCentralPubMed
147.
Zurück zum Zitat Zhang W, Moskowitz RW, Nuki G et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16:137–162 PubMed Zhang W, Moskowitz RW, Nuki G et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16:137–162 PubMed
Metadaten
Titel
DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR-Therapie muskuloskelettaler Schmerzen
verfasst von
Dr. W. W. Bolten
K. Krüger
S. Reiter-Niesert
D. O. Stichtenoth
Kommission Pharmakotherapie der DGRh
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 1/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-015-0018-6

Weitere Artikel der Ausgabe 1/2016

Zeitschrift für Rheumatologie 1/2016 Zur Ausgabe

Mitteilungsseiten DRL

Mitteilungsseiten DRL

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

Fallbeispiele zur Gastroenterologie

Praxisnahe medizinische Fortbildung durch alltägliche bis außergewöhnliche klinische Fallbeispiele